Top > Search of International Patents > METHOD FOR INDUCING MACROPHAGES, INDUCER FOR ANTI-INFLAMMATORY MACROPHAGES AND PHARMACEUTICAL COMPOSITION

METHOD FOR INDUCING MACROPHAGES, INDUCER FOR ANTI-INFLAMMATORY MACROPHAGES AND PHARMACEUTICAL COMPOSITION

Foreign code F200010242
File No. (S2019-0118-N0)
Posted date Oct 30, 2020
Country WIPO
International application number 2020JP009639
International publication number WO2020184425
Date of international filing Mar 6, 2020
Date of international publication Sep 17, 2020
Priority data
  • P2019-042795 (Mar 8, 2019) JP
Title METHOD FOR INDUCING MACROPHAGES, INDUCER FOR ANTI-INFLAMMATORY MACROPHAGES AND PHARMACEUTICAL COMPOSITION
Abstract This method for inducing macrophages involves culturing macrophages in the presence of exosomes produced from interferon γ-added mesenchymal stem cells, and inducing anti-inflammatory macrophages. This inducer for anti-inflammatory macrophages contains exosomes produced from interferon γ-added mesenchymal stem cells as an effective ingredient. This pharmaceutical composition comprises said inducer.
Outline of related art and contending technology BACKGROUND ART
Mesenchymal stem cells (MSC) can be collected not only from bone marrow but also from medical wastes such as adipose tissue and umbilical cord tissue, have low antigenic properties, can also use other cells, and have various roles such as anti-inflammatory, antifibrosis, angiogenesis, antioxidation, and the like. However, it has been reported that MSC is slightly different depending on the cell type from which MSC is derived, and the properties of MSC are changed when they enter into culture conditions and living bodies, and the mechanism of the effect has not been clarified yet. MSC is expected to act on many immune cells through the production of cytokines, chemokines, growth factors, exosomes, and the like as "conducting cells", but the influence on macrophages is paid attention to the pathology of liver cirrhosis.
So far, the inventors have found that MSC changes the polarity of myeloid-derived cultured macrophages to), also referred to as anti-inflammatory macrophages ("M2 macrophages", thereby acting on fibrogenesis improvement and regeneration promotion during liver cirrhosis, for example, see) Non-Patent Document 1.
However, it is known that most of MSC are delivered to the lungs when administered intravenously and very few of MSC are delivered to the liver. Nevertheless, it is presumed that some MSC expression substance is involved in liver cirrhosis because of showing the above effect on liver cirrhosis, but the detailed mechanism of which substance changes the polarity of macrophages has not been clarified.
Scope of claims (In Japanese)[請求項1]
 インターフェロンガンマを添加した間葉系幹細胞から産生されたエクソソーム存在下で、マクロファージを培養し、抗炎症性マクロファージに誘導する、マクロファージの誘導方法。

[請求項2]
 インターフェロンガンマを添加した間葉系幹細胞から産生されたエクソソームを有効成分として含有する、抗炎症性マクロファージの誘導剤。

[請求項3]
 請求項2に記載の誘導剤を含む、医薬組成物。

[請求項4]
 抗炎症用である、請求項3に記載の医薬組成物。

[請求項5]
 抗線維化用である、請求項3に記載の医薬組成物。

[請求項6]
 肝炎又は肝硬変の治療又は予防用である、請求項3~5のいずれか一項に記載の医薬組成物。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NIIGATA UNIVERSITY
  • Inventor
  • TERAI Syuji
  • TSUCHIYA Atsunori
  • TAKEUCHI Suguru
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close